IDYA Quote, Financials, Valuation and Earnings

Kestra Medical Technologies Ltd. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -145.29%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Kestra Medical Technologies Ltd.'s return on equity of -105.99%.

IDEAYA Biosciences, Inc. has a consensus price target of $49.94, signalling upside risk potential of 55.24%. On the other hand Kestra Medical Technologies Ltd. has an analysts' consensus of $29.00 which suggests that it could grow by 13.86%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Kestra Medical Technologies Ltd., analysts believe IDEAYA Biosciences, Inc. is more attractive than Kestra Medical Technologies Ltd..

IDEAYA Biosciences, Inc. has a beta of 0.097, which suggesting that the stock is 90.337% less volatile than S&P 500. In comparison Kestra Medical Technologies Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Kestra Medical Technologies Ltd. pays out 1.45% of its earnings as a dividend. Kestra Medical Technologies Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Kestra Medical Technologies Ltd. quarterly revenues of $22.6M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Kestra Medical Technologies Ltd.'s net income of -$32.8M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Kestra Medical Technologies Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.25x versus 17.61x for Kestra Medical Technologies Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -9.34%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Pfizer Inc.'s return on equity of 10.84%.

IDEAYA Biosciences, Inc. has a consensus price target of $49.94, signalling upside risk potential of 55.24%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 5.48%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Pfizer Inc..

IDEAYA Biosciences, Inc. has a beta of 0.097, which suggesting that the stock is 90.337% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.32% to investors and pays a quarterly dividend of $0.43 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.25x versus 2.48x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Rezolute, Inc.'s return on equity of -63.8%.

IDEAYA Biosciences, Inc. has a consensus price target of $49.94, signalling upside risk potential of 55.24%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 36.22%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Rezolute, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Rezolute, Inc..

IDEAYA Biosciences, Inc. has a beta of 0.097, which suggesting that the stock is 90.337% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.658%.

IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Rezolute, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Rezolute, Inc.'s net income of -$18.2M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.25x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -45.06%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

IDEAYA Biosciences, Inc. has a consensus price target of $49.94, signalling upside risk potential of 55.24%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 15.86%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..

IDEAYA Biosciences, Inc. has a beta of 0.097, which suggesting that the stock is 90.337% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.

IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 13.25x versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.